



(51) International Patent Classification:

C07J 63/00 (2006.01) A61P 31/18 (2006.01)
A61K 31/58 (2006.01) C07F 5/02 (2006.01)
A61K 31/56 (2006.01) C07C 309/65 (2006.01)

(21) International Application Number:

PCT/US2015/025029

(22) International Filing Date:

9 April 2015 (09.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/978,306 11 April 2014 (11.04.2014) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **SIT, Sing-Yuen**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **CHEN, Yan**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **CHEN, Jie**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SWIDORSKI, Jacob**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **VENABLES, Brian Lee**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SIN, Ny**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **MEANWELL, Nicholas A.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway,

Wallingford, Connecticut 06492 (US). **REGUEIRO-REN, Alicia**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **HARTZ, Richard A.**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **XU, Li**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **LIU, Zheng**; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).


(74) Agents: **LEVIS, John F.** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT



(57) Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from C₄₋₈ cycloalkyl, C₄₋₈ cycloalkenyl, C₄₋₉ spirocycloalkyl, C₄₋₉ spirocycloalkenyl, C₄₋₈ oxacycloalkyl, C₄₋₈ dioxacycloalkyl, C₆₋₈ oxacycloalkenyl, C₆₋₈ dioxacycloalkenyl, C₆ cyclodialkenyl, C₆ oxacyclodialkenyl, C₆₋₉ oxaspirocycloalkyl and C₆₋₉ oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is -C₁₋₆ alkyl- halo. These compounds are useful for the treatment of HIV and AIDS.



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*